Real-World Experience with Canakinumab in Familial Mediterranean Fever: A Single-Center Study

Authors : Tuğba Ocak, Ayşe Bulur, Burcu Yağız, Belkis Nihan Coskun, Hüseyin Ediz Dalkılıç, Yavuz Pehlivan
Pages : 87-92
Doi:10.32708/uutfd.1649876
View : 55 | Download : 108
Publication Date : 2025-05-27
Article Type : Research Paper
Abstract :Familial Mediterranean fever (FMF) is an autoinflammatory disorder caused by mutations in the Mediterranean fever gene (MEFV), leading to excessive interleukin-1 beta (IL-1β) production. While colchicine is the primary treatment for FMF, a subset of patients exhibits resistance or intolerance, necessitating alternative therapeutic strategies. Canakinumab, a selective IL-1β inhibitor, has emerged as a potential treatment option. This study aims to evaluate canakinumab\\\'s real-world efficacy and safety in colchicine-resistant or colchicine-intolerant FMF patients. A retrospective, single-center study was conducted on FMF patients aged over 18 who initiated canakinumab treatment between January 2013 and October 2023. A total of 34 patients experiencing colchicine resistance or intolerance criteria were analyzed. Clinical and laboratory parameters, including Pras scores, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum amyloid A (SAA), were assessed before and after canakinumab treatment. Statistical analyses were performed using the Wilcoxon test and paired sample t-test. Canakinumab treatment significantly reduced Pras scores (p<0.001), ESR (p<0.001), CRP (p<0.001), and SAA levels (p<0.001). A decrease was observed post-treatment among patients with proteinuria, though not statistically significant (p=0.140). Treatment was discontinued in three patients due to active disease or adverse effects. No serious infections were reported. In conclusion, canakinumab could be a promising treatment option in colchicine-resistant or colchicine-intolerant FMF patients.
Keywords : Kanakinumab, Kolşsin intolreansı, Kolşissin direnci, Ailevi Akdeniz ateşi

ORIGINAL ARTICLE URL